CXCR4 CCR5 Modulators Overcoming HIV Tropism Switching
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for HIV and cancer treatment, particularly those targeting CXCR4 and CCR5 receptors, face limitations such as tropism switching and resistance, necessitating the development of more effective modulators for viral infections and cancer management.
Innovation Solution
Development of pharmaceutical compositions comprising specific compounds that modulate CXCR4 and CCR5 receptors, including derivatives and pharmaceutically acceptable salts, which can be administered alone or in combination with other active ingredients to treat or prevent viral infections and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies targeting CXCR4 and CCR5 receptors are used for HIV treatment, then viral entry is inhibited, but tropism switching and resistance occur reducing long-term efficacy
Solution Approach 1:
The patent employs parameter changes by developing novel chemical compounds with modified molecular structures (Formula I with varying substituents R1-R6, ring systems A-D, and linkers L1-L3) to alter binding affinity and selectivity for chemokine receptors, thereby overcoming resistance and preventing tropism switching while maintaining therapeutic efficacy
Solution Approach 2:
The invention uses composite molecular structures combining multiple functional groups (heterocyclic rings, aromatic systems, linker moieties) within single pharmaceutical compounds to create multi-functional modulators that can simultaneously target viral entry pathways and prevent resistance development
2Reliability
If entry inhibitors targeting gp120 binding to CD4 and chemokine receptors are developed, then viral entry is blocked, but complexity of molecular events requires multiple targets increasing drug design complexity
Solution Approach 1:
The patent applies universality by designing compounds that can simultaneously inhibit multiple interaction steps in the viral entry process (gp120-CD4 binding, gp120-chemokine receptor binding) through a single molecular entity, thereby blocking viral entry at multiple points without requiring separate drugs for each target
Solution Approach 2:
The invention merges multiple pharmacological activities into single compounds by combining pharmacophores that target different molecular events (CD4 binding inhibition, chemokine receptor antagonism) within one molecular structure, simplifying the therapeutic regimen while addressing the complexity of viral entry mechanisms
Data Source
Figure 1
Figure 2A~2Ad
Figure 2B~2Be
AI summary
The disclosure relates to chemokine receptor modulators and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing chemokine related conditions, typically prevention or treatment of viral infections such as HIV or for managing cancer.